Drug & supplement interaction

Limosilactobacillus Reuteri + Ibandronate

Ibandronate brand names: Boniva, Boniva IV.

No Known Interaction
The bottom line No known interaction

We found no known interaction between Limosilactobacillus Reuteri and Ibandronate in our sources. Absence of a documented interaction is not the same as proven safety, and does not guarantee one does not exist. Do not start, stop, or change a medication or supplement based on this page; confirm with your pharmacist or doctor first. Additionally, although there is no interaction, the label for Ibandronate states a food rule worth keeping to, and the two are separately associated with some of the same side effects, which would make a new symptom harder to attribute to one or the other.

Know someone taking this? Share
Interaction report

Limosilactobacillus Reuteri and Ibandronate

We checked these two against our interaction database. Here is what we found.

No Known Interaction Found

We did not find a documented interaction between Ibandronate and Limosilactobacillus Reuteri in our sources. This does not guarantee that the combination is completely free of risk — there is often limited research on supplements and herbal products, especially around drug interactions.

If you decide to take both, the practical routine is simple: add one new thing at a time and note the date you started it. If the combination is going to disagree with you, it usually shows in the first days to a couple of weeks — and a start date turns “I’ve been feeling off” into something a pharmacist can actually work with. Do not stop a prescribed medicine on your own.

Always talk with your pharmacist or doctor before making changes to your medications or supplements, particularly if you take several medications or have an ongoing health condition.

Limosilactobacillus Reuteri safety at a glance

Limosilactobacillu... overall Use caution Generally well tolerated in healthy people, but caution is needed in those who are seriously ill or immunocompromised.
Pregnancy Possibly Safe When used orally and appropriately. Read the full pregnancy detail
Breastfeeding Possibly Safe When used orally and appropriately. Although clinical research during lactation is lacking, no safety concerns have been shown in clinical research involving in... Read the full breastfeeding detail

Pregnancy & breastfeeding ratings are from Natural Medicines (Therapeutic Research Center) — the full detail is in the Special populations card below. Safety guidance is general; always confirm with your pharmacist or doctor for your situation.

Still wondering about combining Ibandronate and Limosilactobacillus Reuteri? Ask Dr. Brian Staiger, PharmD, BCPS directly ›
How we checked

Why No Interaction Is Listed for Ibandronate

Interactions in our licensed database are recorded against drug classes, not just single drug names. Ibandronate is filed under 2 classifications — bisphosphonates, oral drugs. Limosilactobacillus Reuteri has documented interactions with 1 drug class — the most serious being antibiotic drugs (moderate) — and none of Ibandronate’s classifications are among them.

Classification data comes from our licensed Natural Medicines dataset. A medication can belong to classes beyond those recorded there, so this describes how the check was run — it is not a safety guarantee.

Keep it in perspective

Limosilactobacillus Reuteri Does Interact With Other Medications

Limosilactobacillus Reuteri has 182 moderate known drug interactions in our database — Ibandronate isn’t one of them. If you take anything else, check it against the full list below.

Taking anything else?

Check Another of Your Medications Against Limosilactobacillus Reuteri

Covers the 2,830 medications we’ve checked against Limosilactobacillus Reuteri. Pick one to open its full report.

What to actually watch for

No Interaction Found — But Data Suggests Limosilactobacillus Reuteri and Ibandronate May Share Several of the Same Side Effects

This is not an interaction. Neither one changes how your body handles the other, and nothing here says they react together. What our sources do show is that each has separately been linked to the effects below — so taking both can make those effects more likely to turn up, and harder to pin on one or the other if they do. One of them is worth acting on rather than waiting out — marked below.

  • A higher chance of infection Worth acting on Additional detail

    Limosilactobacillus Reuteri

    “Since Limosilactobacillus reuteri preparations contain live and active microorganisms, there is some concern that they might cause pathogenic infection in some patients. Some lactobacilli species have been isolated in some cases of bacteremia, sepsis, splenic abscess, endocarditis, necrotizing fasciitis, pancreatic necrosis, and meningoencephalitis.”

    Limosilactobacillus Reuteri · Natural Medicines adverse-effect record, reported in sepsis.

    1 source cited
    1. 107543. Rossi F, Amadoro C, Gasperi M, Colavita G. Lactobacilli infection case reports in the last three years and safety implications. Nutrients. 2022;14(6):1178. PubMed

    Ibandronate

    Listed in the ADVERSE REACTIONS section of the FDA label for Ibandronate. Read the label on DailyMed ›

  • Constipation / Diarrhea Additional detail

    Limosilactobacillus Reuteri

    “Orally, taking Limosilactobacillus reuteri alone or in combination with other probiotics may cause gastrointestinal side effects including diarrhea and constipation; however, these events are uncommon.”

    Limosilactobacillus Reuteri · Natural Medicines adverse-effect record, reported in constipation.

    2 sources cited
    1. 90235. Beerepoot MA, ter Riet G, Nys S, van der Wal WM, de Borgie CA, de Reijke TM,Prins JM, Koeijers J, Verbon A, Stobberingh E, Geerlings SE. Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in p DOI
    2. 107507. Ojetti V, Gigante G, Gabrielli M, et al. The effect of oral supplementation with Lactobacillus reuteri or tilactase in lactose intolerant patients: randomized trial. Eur Rev Med Pharmacol Sci. 2010;14(3):163-70.

    Ibandronate

    Listed in the ADVERSE REACTIONS section of the FDA label for Ibandronate. Read the label on DailyMed ›

Effects for Ibandronate come from the ADVERSE REACTIONS section of its FDA label; effects for Limosilactobacillus Reuteri come from the Natural Medicines adverse-effect record, quoted above. Wording is matched across sources by our own clinical vocabulary, so treat this as a prompt to pay attention, not a diagnosis.

Special populations

Limosilactobacillus Reuteri in Pregnancy & Breastfeeding

Pregnancy Possibly Safe

When used orally and appropriately.

Lactation Possibly Safe

When used orally and appropriately. Although clinical research during lactation is lacking, no safety concerns have been shown in clinical research involving infants up to 3 months of age.

DISCLAIMER: This tool is intended for informational purposes only, and should not be interpreted as specific medical advice. Patients should consult with a qualified healthcare provider before making decisions about therapies and/or health conditions.© 2026 Therapeutic Research Center

How to take them

Some Ibandronate Products Have a Food Rule — Limosilactobacillus Reuteri Should Not Break It

At least one FDA label for a product containing Ibandronate says to take it on an empty stomach. Most supplements — Limosilactobacillus Reuteri included — are taken with a meal, so the easy mistake is swallowing both together at breakfast. Where that rule applies, keep Ibandronate on its own and move Limosilactobacillus Reuteri to a meal later in the day.

This may not be true of your version. Food instructions belong to the product, not the ingredient: two Ibandronate products can carry different directions, and extended-release forms often differ from immediate-release ones. The label we read is quoted below — check the directions on your own box or bottle, or ask your pharmacist, for how to take the exact product you were given.

2 DOSAGE AND ADMINISTRATION Take one 150 mg tablet once monthly on the same day each month ( 2.1 ) Instruct patient to: ( 2.2 ) Swallow whole tablet with 6 to 8 oz of plain water only, at least 60 minutes before the first food, beverage, or medication of day.

From the Dosage and Administration section of the FDA label we read for Ibandronate — where that label names a specific product, the instruction is that product's. Read the label on DailyMed ›

A food rule is not an interaction — it is about how much of the medicine you absorb. The directions that came with your own product, and your pharmacist, outrank anything on this page.

Everything else you take

See Every Supplement That Interacts With Ibandronate

This page covers Limosilactobacillus Reuteri only. If you take other supplements — a multivitamin, a sleep aid, something for joints — the Ibandronate page lists 23 supplements it has a documented interaction with, worst first, each one explained.

The most serious there right now: Activated Charcoal (major), Calcium (moderate), Coffee Charcoal (moderate), Dolomite (moderate) and European Mandrake (moderate).

By severity: 1 major · 13 moderate · 9 minor.

From our pharmacist’s overview on the Ibandronate page

“Ibandronate (Boniva) treats osteoporosis, and it is famously hard to absorb, which is why you take it fasting with plain water. Nearly all 23 supplements on this list attack that same weak point, so treat them with real care, because the danger is not a new side effect but a dose that quietly never reaches your bones.”

Reviewed by 2 · Jul 18, 2026

Open the Ibandronate interaction page

How much people look this up

Where Limosilactobacillus Reuteri and Ibandronate Sit Against Everything Else

Out of every supplement and medication people look up on HelloPharmacist, here is where these two land this week — and which way each has been moving.

Supplement Limosilactobacillus Reuteri
Steady interest

#978 of 1,452 supplements looked up here in the last 7 days

29 days ago today
Medication Ibandronate
Steady interest

#1,864 of 2,830 medications looked up here in the last 7 days

29 days ago today

Position among everything looked up on this site, not a measure of how commonly either one is used or how important it is. A supplement can climb this list because of a news story. It counts every request to the page, automated ones included, and nothing here identifies anyone.

Where does our data come from?
  • Source: the Natural Medicines (TRC Healthcare) clinical database — the evidence-graded professional reference for herb & supplement interactions.
  • Citation library: 103,510 references behind our interaction content, 65,311 of them resolved to verified PubMed/DOI sources. See every Limosilactobacillus Reuteri reference on this page ↓
  • Freshness: we automatically re-check this combination every week — this pair was last verified September 13, 2026. The Limosilactobacillus Reuteri and Ibandronate records this page draws on were last updated July 11, 2026.
  • What “no known interaction” means: no documented interaction in the sources above — not a guarantee of safety. Supplements are studied far less than prescription drugs, so we say exactly what the evidence supports, and nothing more.
Data structure & sourcing designed and verified by .
Supplement

About Limosilactobacillus Reuteri

What is Limosilactobacillus Reuteri?

  • Infant colic
  • Diarrhea (including antibiotic-associated)
  • Digestive health
  • Oral and gum health
  • Constipation
  • Immune support

Limosilactobacillus reuteri (formerly Lactobacillus reuteri) is a probiotic bacterium found in the human gut and certain fermented foods. It has the most supportive evidence for reducing crying in breastfed infants with colic and for some types of diarrhea, while many other uses remain unproven. It is generally well tolerated in healthy people, but people who are very ill or immunocompromised should talk to a doctor first.

Limosilactobacillus reuteri · Lactobacillaceae · Live bacterial cells (probiotic strains) · Chewable tablets, drops/oils, capsules, powders, fortified foods and yogurt

An interaction check asks whether these two react with each other — it does not ask whether Limosilactobacillus Reuteri is a good idea for someone in your situation. Here is what our Limosilactobacillus Reuteri record says about it on its own.

Limosilactobacillus Reuteri: dosing

There is no single official dose for L. reuteri. Do not assume a higher dose is better.

From our Limosilactobacillus Reuteri monograph — the full record covers uses, side effects and every documented interaction.

Read the full Limosilactobacillus Reuteri monograph & all interactions
Medication

About Ibandronate

What Is Ibandronate Used For?

Brand names: Boniva, Boniva IV

Ibandronate sodium tablets (brands: Boniva, Ibandronate sodium) are approved for both the treatment and prevention of osteoporosis in postmenopausal women. They increase bone mineral density (BMD) and reduce the risk of spinal fractures.

Ibandronate Sodium injection (given intravenously) is approved for the treatment of osteoporosis in postmenopausal women. It also increases bone mineral density and reduces the incidence of vertebral (spinal) fractures. The injection is not approved for prevention.

See full Ibandronate drug information
Keep checking

Other Drugs & Limosilactobacillus Reuteri

Browse every other medication we’ve checked against Limosilactobacillus Reuteri — both the ones with a known interaction and the ones without. Select any drug for the full detail.

0Major
182Moderate
0Minor
2,647No known interaction
Moderate

182 interactions

Showing 60 of 182 moderate interactions — see all 182 on the Limosilactobacillus Reuteri page.

No interaction 2,647 drugs checked — show the list
Evidence & sources

Limosilactobacillus Reuteri References

The 14 references that drive our Limosilactobacillus Reuteri monograph and interaction data, from the evidence-graded Natural Medicines (TRC Healthcare) database. Citations with a link open the study on PubMed or the publisher’s site.

  1. Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.
  2. Savino F, Cordisco L, Tarasco V, et al. Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial. Pediatrics 2010;126:e526-33.
  3. Savino F, Pelle E, Palumeri E, et al. Lactobacillus reuteri (American Type Culture Collection Strain 55730) versus simethicone in the treatment of infantile colic: a prospective randomized study. Pediatrics 2007;119:e124-30.
  4. Beerepoot MA, ter Riet G, Nys S, van der Wal WM, de Borgie CA, de Reijke TM,Prins JM, Koeijers J, Verbon A, Stobberingh E, Geerlings SE. Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in p DOI
  5. Chau K, Lau E, Greenberg S, Jacobson S, Yazdani-Brojeni P, Verma N, Koren G.Probiotics for infantile colic: a randomized, double-blind, placebo-controlled trial investigating Lactobacillus reuteri DSM 17938. J Pediatr 2015;166(1):74-8. PubMed
  6. Indrio F, Di Mauro A, Riezzo G, Civardi E, Intini C, Corvaglia L, Ballardini E, Bisceglia M, Cinquetti M, Brazzoduro E, Del Vecchio A, Tafuri S, Francavilla R. Prophylactic use of a probiotic in the prevention of colic, regurgitation, and functional const
  7. Oncel MY, Sari FN, Arayici S, Guzoglu N, Erdeve O, Uras N, Oguz SS, Dilmen U. Lactobacillus Reuteri for the prevention of necrotising enterocolitis in very low birthweight infants: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed. 2014;99(2
  8. Sung V, Hiscock H, Tang ML, Mensah FK, Nation ML, Satzke C, Heine RG, Stock A,Barr RG, Wake M. Treating infant colic with the probiotic Lactobacillus reuteri: double blind, placebo controlled randomised trial. BMJ. 2014 1;348:g2107. PubMed
  9. Szajewska H, Gyrczuk E, Horvath A. Lactobacillus reuteri DSM 17938 for the management of infantile colic in breastfed infants: a randomized, double-blind,placebo-controlled trial. J Pediatr. 2013;162(2):257-62. PubMed
  10. Husain S, Allotey J, Drymoussi Z, et al. Effects of oral probiotic supplements on vaginal microbiota during pregnancy: a randomised, double-blind, placebo-controlled trial with microbiome analysis. BJOG. 2020;127(2):275-284. PubMed
  11. Ojetti V, Gigante G, Gabrielli M, et al. The effect of oral supplementation with Lactobacillus reuteri or tilactase in lactose intolerant patients: randomized trial. Eur Rev Med Pharmacol Sci. 2010;14(3):163-70.
  12. Rossi F, Amadoro C, Gasperi M, Colavita G. Lactobacilli infection case reports in the last three years and safety implications. Nutrients. 2022;14(6):1178. PubMed
  13. Sheyholislami H, Connor KL. Are probiotics and prebiotics safe for use during pregnancy and lactation? A systematic review and meta-analysis. Nutrients. 2021;13(7):2382. PubMed
  14. Yefet E, Colodner R, Strauss M, Gam Ze Letova Y, Nachum Z. A randomized controlled open label crossover trial to study vaginal colonization of orally administered Lactobacillus reuteri RC-14 and rhamnosus GR-1 in pregnant women at high risk for preterm la

Medication overviews come from MedlinePlus (NIH); supplement label data from the NIH Dietary Supplement Label Database. Content is written and reviewed by licensed HelloPharmacist pharmacists — see our data sources and editorial standards.

Pharmacist Counseling Corner

Taking Limosilactobacillus Reuteri and Ibandronate Together: Common Questions

Is it safe to take Limosilactobacillus Reuteri with Ibandronate?
We do not list a known interaction between Limosilactobacillus Reuteri and Ibandronate. That does not guarantee the combination is risk-free, so confirm with your pharmacist or doctor — especially if you take other medications or have a health condition.
Do Limosilactobacillus Reuteri and Ibandronate have any of the same side effects?
Yes — our sources link each of them separately to 3 of the same effects. That is not an interaction: neither changes how your body handles the other. It does mean that if one of those effects turns up, it can be harder to tell which one is behind it. They are listed on this page with the source behind each.
Should I take Limosilactobacillus Reuteri and Ibandronate at the same time of day?
At least one FDA label for a product containing Ibandronate says to take it on an empty stomach, and supplements are usually taken with a meal — so taking them together at breakfast is the easy mistake. Where that applies, keep Ibandronate on its own and move Limosilactobacillus Reuteri to a meal later in the day. Food instructions belong to the product rather than the ingredient, so check the directions on your own box. This is about absorption, not an interaction.
How was the Limosilactobacillus Reuteri and Ibandronate combination checked?
Interactions in our licensed database are recorded against drug classes. Ibandronate is filed under 2 classifications, and Limosilactobacillus Reuteri has documented interactions with 1 drug class — none of Ibandronate's classifications are among them. A medication can belong to classes beyond those recorded in our dataset, so this describes how the check was run rather than guaranteeing safety.
Does Limosilactobacillus Reuteri interact with any other medications?
Yes. Limosilactobacillus Reuteri has 182 documented drug interactions in our database — Ibandronate is simply not one of them. If you take anything else, it is worth checking each one; they are all listed on this page.
Does Ibandronate interact with any supplements?
Yes. Ibandronate has documented interactions with 23 supplements in our database — Limosilactobacillus Reuteri is not one of them. The Ibandronate interaction page linked on this page lists every one, ranked by severity.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Still Have a Question About Ibandronate and Limosilactobacillus Reuteri?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

This information is for education only and is not a substitute for professional medical advice. Always check with your pharmacist or doctor before starting, stopping, or combining supplements and medications.